The findings have important implications for elucidating a novel molecular mechanism of CDK2-mediated suppression of PXR and providing some theoretical explanation with respect to the DDIs in cancer therapy, and ultimately indicate that CDK2-inhibitors might induce a wide range of DDIs in a PXR-related way. The gene discussed is NR1I2; the disease is cancer.